Henry Peck’s Post

Strong assessment Henry Peck LSI on the fastest growing #neurotech market , #neuromodulation The global #neuromodulation market continues to experience significant growth 📈 and attract exciting new entrants. With #innovative applications of #neuromodulation devices to treat chronic conditions that respond poorly to traditional medications, the market is seeing strong investment and M&A activity. .#DisruptiveTechnology #neurotech Varia Ventures

Dive into PurMinds' Clinical Pipeline! We are developing next generation therapeutics for neurological disorders harnessing cutting-edge neuroscience technology and the regenerative capacity of psychedelics and neuroplastogens. PUR101: Unleashing Hope for Parkinson's-Related Depression Discover the power of Pur101, our exclusive botanical psilocybin formulation. Paving the way for innovative solutions, it holds promise for Depression in Parkinson's patients, which occurs in approx. 90% of Parkinson's patients. PUR400: Revolutionizing ALS and CIPN Treatment Embark on a journey with Pur400, our second and third generation HDAC6 inhibitors. Engineered to combat Amyotrophic Lateral Sclerosis (ALS) and Chemotherapy-Induced Peripheral Neuropathy (CIPN), it represents a significant leap in therapeutic advancements. PUR501: Navigating Non-Hallucinogenic Horizons Experience the future of psychedelic-inspired therapy with Pur501. A non-hallucinogenic psychedelic analogue, it opens new doors for treatment possibilities. Find out more about our development program by visiting Purminds.com. #PurMindsPipeline #NeuropharmaceuticalInnovation #ResearchAndDevelopment

🚀 Exciting News! We are delighted to share that our research project "FAITH - Fatigue Therapy: AI-assisted Diagnosis and Treatment of Oncological Fatigue Syndrome" has been approved for research funding program ZukunftBIO.NRW by Ministerium für Wirtschaft NRW: https://lnkd.in/eBMZ_4QC 🎉 🔬 Collaborating with the renowned Fraunhofer-Institute for Microelectronic Circuits and Systems, Forschungszentrum Jülich & University clinic of Essen, we're diving into groundbreaking territory to tackle the challenges posed by the onerous Oncological Fatigue Syndrome. This innovative initiative combines the power of AI with cutting-edge diagnostics and therapeutic approaches to make a real impact on the lives of those affected by this condition. 🌐 With the prevalence of cancer-related fatigue being a significant concern, our collaborative efforts aim to revolutionize how we understand, diagnose, and treat this syndrome. The fusion of advanced AI algorithms, the expertise of Fraunhofer Institute, the research capabilities of FZ Jülich, and the medical insights from University Hospital Essen promises a comprehensive and effective approach. 🤝 This project exemplifies the spirit of collaboration across academia, research institutions, and medical facilities. By harnessing our collective strengths, we're not only advancing scientific knowledge but also offering hope to individuals grappling with the challenges of oncological fatigue. Great to see some other well-known faces on the list PROSION Therapeutics or Detechgene Tim Fellerhoff Dr. Thomas Lenzen Caroline Ressing Juergen Dukart Karsten Seidl #digitalhealth #digitaltherapeutics #oncology

🚀 Exciting News! Fimo Health , a LUMO Labs portfolio company, announced that their research project "FAITH - Fatigue Therapy: AI-assisted Diagnosis and Treatment of Oncological Fatigue Syndrome" has been approved for research funding program ZukunftBIO.NRW by Ministerium für Wirtschaft NRW: https://lnkd.in/eBMZ_4QC 🎉 🔬 Collaborating with the renowned Fraunhofer-Institute for Microelectronic Circuits and Systems, Forschungszentrum Jülich & University clinic of Essen, Fimo Health will be diving into groundbreaking territory to tackle the challenges posed by the onerous Oncological Fatigue Syndrome. This innovative initiative combines the power of #AI with cutting-edge #diagnostics and #therapeutic approaches to make a real impact on the lives of those affected by this condition. 🌐 With the prevalence of cancer-related fatigue being a significant concern, our collaborative efforts aim to revolutionize how we understand, diagnose, and treat this syndrome. The fusion of advanced AI algorithms, the expertise of Fraunhofer Institute, the research capabilities of FZ Jülich, and the medical insights from University Hospital Essen promises a comprehensive and effective approach. 🤝 This project exemplifies the spirit of collaboration across academia, research institutions, and medical facilities. By harnessing our collective strengths, we're not only advancing scientific knowledge but also offering hope to individuals grappling with the challenges of oncological fatigue. Great to see some other well-known faces on the list PROSION Therapeutics or Detechgene #digitalhealth #digitaltherapeutics #oncology #goodthingsarecoming Margriet Sven Meron Thomas Dagmar Pim Sabine Federico Jan Christian Florian Florian Pieter Anita Klaas Bart Alexander Benedict Tom Harry Ulrike Michael Frederieke Tizian Andreas Steffen Maximilian Parul Michel Christian MaartenAbass Benno Stefan https://lnkd.in/ekBVFYBC

Big News in Regenerative Medicine! Previously, I mentioned how exciting I find regenerative medicine. Big news out of Japan today. Cuorips, a Japanese startup connected to Osaka University, is set to be the first in the world to seek regulatory approval for a therapy made from human induced pluripotent stem (iPS) cells. They’ve developed a cardiac tissue sheet that can be grafted onto the hearts of patients with coronary artery disease, offering a less invasive treatment option with promising results- https://lnkd.in/gyAUBUwK Inteligex. is also making strides in this space. We're focused on using iPSCs to treat CNS diseases like spinal cord injury, ALS, and MS. Seeing advancements like Cuorips' reinforces the potential of regenerative medicine to change lives. Let’s keep pushing forward and exploring new possibilities! 🚀 Paul Bradshaw#RegenerativeMedicine #iPSCs #HealthcareInnovation #Inteligex

1️⃣ Nyxoah's Genio hypoglossal nerve stimulation system has achieved its endpoints in a sleep apnea study, paving the way for US marketing authorization to treat obstructive sleep apnea. 2️⃣ Tempo Therapeutics has received funding, with Galaxy Sirius Partners and Johnson & Johnson Innovation leading the round, to propel its tissue scaffold candidates into clinical studies. 3️⃣ Inspira is pursuing approval from Israel's AMAR for its INSPIRA ART100 device, which boasts a large touchscreen and vibrant graphical displays. 4️⃣ Siemens Healthineers is set to shut down its fast-track diagnostics division, as part of a strategic decision by the German multinational company. 5️⃣ Labcorp has introduced a pTau217 blood biomarker test for Alzheimer's, offering a blood-based method to measure levels of phosphorylated tau 217, a biomarker associated with Alzheimer's disease. 6️⃣ The University of Saskatchewan and SOPHiA GENETICS have formed a partnership to enhance an ovarian cancer trial, aiming to improve genetic testing and personalize treatment in Canada. 🔓 Unlock the potential of seamless post-market incident handling with Smarteeva's latest innovations that are setting the stage for a new era in healthcare technology. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr

The oncology devices market is projected to experience significant expansion in the coming years, with an anticipated growth of $298.31 billion by 2028, reflecting a compound annual growth rate (CAGR) of 18.0%. Growth during the forecast period can be attributed to minimally invasive surgical techniques, biodegradable implants, global healthcare expansion, value-based care models, and digital health integration. Major trends during the forecast period include advancements in radiation therapy, early detection technologies, oncology devices, liquid biopsies, and AI-powered decision support. Learn more about the market: https://buff.ly/3T9RikG . . . #oncologydevices #radiationtherapy #biodegradableimplants #detectiontechnologies #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

Another great article featuring Argenica CEO, Dr Liz Dallimore. Market Open Australia Network describes Dr Dallimore as "a neuroscientist on the verge of bringing life-changing brain trauma therapy to market". Learn more about lead led Dr Dallimore to working with Argenica Therapeutics, and what lessons she has learnt so far through our road to commercialisation. #ARG007 #AGN #ASX #technology #biotechnology #noveltherapeutics #ARG007

Alongside the many breakthroughs in the #Alzheimers #DrugDevelopment space, the diagnostics landscape is rapidly evolving, too. Researchers are exploring ways to improve the accessibility and scalability of #amyloid blood tests, and working to validate the complementary #biomarkers that will support drug development. Our Co-Founder and Chief Science Officer, Howard Fillit, MD, connected with Rowan Walrath of C&EN to discuss the ADDF's Diagnostics Accelerator (DxA) and its funding of blood-based biomarkers and #digital diagnostic tools, offering his prediction that #BloodTests will eventually replace the current gold standard PET scans and spinal taps for Alzheimer's #diagnosis. Throughout the article, diagnostic and biomarker research by ADDF- and DxA-funded investigators and biotechs like C2N Diagnostics, ALZpath Inc., Quanterix, RetiSpec, Rhoda Au, and DiaMiR Bio are mentioned. Read the full article here: https://bit.ly/3JaGZXR

Great use of the Revvity IVIS Spectrum and Quantum GXII microCT in a PDX osteosarcoma model. Recognition to the teams at UCSF and Stanford University. #IVIS, #revvity